CSPC Pharmaceutical Group Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CSPCY research report →
About the company
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer.
- CEO
- Lei Cai
- IPO
- 2021
- Employees
- 19,700
- HQ
- Shijiazhuang, SP, CN
Price Chart
- Market Cap
- $11.06B
- P/E
- 20.91
- P/S
- 3.09
- P/B
- 2.40
- EV/EBITDA
- 12.54
- Div Yield
- 3.63%
- Gross Margin
- 65.59%
- Op Margin
- 15.26%
- Net Margin
- 14.92%
- ROE
- 11.47%
- ROIC
- 8.49%
- Revenue
- $25.29B · -12.77%
- Net Income
- $3.78B · -12.72%
- EPS
- $1.32 · -10.81%
- Op Income
- $3.86B
- FCF YoY
- 103.74%
- 52W High
- $5.83
- 52W Low
- $3.26
- 50D MA
- $3.86
- 200D MA
- $4.38
- Beta
- 0.72
- Avg Volume
- 2.16K
Get TickerSpark's AI analysis on CSPCY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our CSPCY coverage
Recent articles, reports, and earnings notes.
No research on CSPCY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CSPCY report →Similar companies
Peers in the same neighborhood.